We believe that Affymetrix is a potential takeover target in view of the general consolidation in the instrument/analytical sector. A potential takeover price would be about
YMI biosciences YMI, reported orphan drug designation being granted to its JAK1/2 inhibitors in Europe. while the stock was up in pre market, it has been taken down after market open - maybe based on profit taking/smart ways of lowering price and getting in by interested Wall st firms. These are the firms that release PR upgrades and downgrades to sell or buy respectively.
MDCO has been seeing improving volume and price action and if you check earlier posts on this blog (using the label) you will note the takeover speculation possibility.
SUPG (now ASTX) is seeing suddenly increased volume on the last day of the month. I don't know if that is window dressing or real action
For those who want to see real time price action, check out level II quotes for free at:
http://www.stockshaven.com/level-ii-quotes
YMI biosciences YMI, reported orphan drug designation being granted to its JAK1/2 inhibitors in Europe. while the stock was up in pre market, it has been taken down after market open - maybe based on profit taking/smart ways of lowering price and getting in by interested Wall st firms. These are the firms that release PR upgrades and downgrades to sell or buy respectively.
MDCO has been seeing improving volume and price action and if you check earlier posts on this blog (using the label) you will note the takeover speculation possibility.
SUPG (now ASTX) is seeing suddenly increased volume on the last day of the month. I don't know if that is window dressing or real action
For those who want to see real time price action, check out level II quotes for free at:
http://www.stockshaven.com/level-ii-quotes
No comments:
Post a Comment
Your comments and opinions here!